Promising Memory-Like NK Cell Therapy Spurs Trial Expansion Available Only at Siteman Kids at St. Louis Children’s Hospital and Siteman Cancer Center
ST. LOUIS — Oncologists at WashU Medicine in St. Louis are expanding an ongoing stem cell transplant study that previously enrolled only patients in remission. The study — shown to be safe and effective and aimed at preventing relapse — now also includes patients with refractory disease and those with two or more transplants. […]
Enrolling Now: ‘High Five’ Study Investigates Short-Term, High-Dose Radiation Therapy for High-Risk Prostate Cancer
A promising study evaluating the use of ultra-hypofractionation radiation therapy for the treatment of high-risk prostate cancer is underway at all six locations of Siteman Cancer Center, based at Barnes-Jewish Hospital and WashU Medicine. Called the “High Five” clinical trial, or NRG-GU-013, the phase III multicenter study will help determine whether five high-dose stereotactic body […]
Immunotherapy improves survival of patients with locally advanced head and neck cancer
Approved drug that revolutionized melanoma treatment may change standard of care for yet another cancer type Research presented at the annual meeting of the American Association for Cancer Research (AACR) in April provides the strongest clinical evidence to date that standard of care therapy could soon be updated for the treatment of resectable locally advanced […]
Vaccine Shows Promise Against Aggressive Breast Cancer
A small clinical trial shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of tumors. Conducted at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, the trial is the first to report results for this type of vaccine — known as […]
New Clinical Trial Focused on Relapse Prevention in Patients with Acute Myeloid Leukemia Undergoing Bone Marrow Transplant
Investigator-Initiated Trial; Only Available at Siteman Cancer Center, Siteman Kids in St. Louis ST. LOUIS — A new and promising clinical trial aimed at preventing relapse in patients diagnosed with acute myeloid leukemia (AML) is now open at Washington University School of Medicine in St. Louis. The trial (NCT06158828) is only available to […]
New Clinical Trials Open for Sarcomas and Solid Tumors
Two exciting early phase clinical trials are underway at Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, that leverage novel classes of drugs and exploit how proteins can be targeted and/or removed to stop uncontrolled cell division that occurs in sarcomas and solid tumors. For BRAF B600 […]
Whole Genome Sequencing for AML/MDS Risk Stratification
ChromoSeq now covered by Medicare; Two Clinical Trials Also Open Two novel clinical trials for patients diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) are open and enrolling patients at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis. The clinical trials are utilizing a breakthrough whole-genome […]
Siteman Cancer Center Advances Head and Neck Tumor Discovery
Soon, a global, stage III randomized clinical trial could result in a paradigm shift in how certain head and neck cancers are treated. The clinical trial, called KEYNOTE-689 and overseen by the Merck pharmaceutical company, is the result of specific research initiated by head and neck cancer specialists at Siteman Cancer Center at Barnes-Jewish Hospital […]
Washington University School of Medicine in St. Louis Awarded $10.9 Million SPORE Grant for Pancreas Cancer
New Clinical Trials Set for Pancreatic Ductal Adenocarcinoma Clinical researchers at Washington University School of Medicine in St. Louis have been awarded a Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI) to continue clinical trials and research aimed at advancing pancreatic cancer care. Awarded in July 2023, it marks the […]
Treating Multiple Myeloma — New Immunotherapies
Multiple myeloma has long vexed medical researchers because of the cancer’s specific ability to both weaken and “hide” from a patient’s own immune system. The result is that while many treatments have been able to treat the disease for some time, patients subsequently relapse. But newer medications now can control the disease for extended […]